- Home
- HRL vs MRNA Comparison
HRL vs MRNA Comparison
Compare HRL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRL | MRNA |
|---|---|---|
| Founded | 1891 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HRL | MRNA |
|---|---|---|
| Price | $23.09 | $33.97 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 13 |
| Target Price | $28.00 | ★ $32.75 |
| AVG Volume (30 Days) | 4.6M | ★ 10.6M |
| Earning Date | 02-26-2026 | 02-13-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $12,106,160,000.00 | $2,232,000,000.00 |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $2.24 | $2.17 |
| P/E Ratio | $26.31 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $21.03 | $22.28 |
| 52 Week High | $32.07 | $47.70 |
Technical Indicators
Market Signals| Indicator | HRL | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 61.46 |
| Support Level | $22.24 | $33.72 |
| Resistance Level | $23.22 | $37.10 |
| Average True Range (ATR) | 0.42 | 1.88 |
| MACD | -0.16 | 0.14 |
| Stochastic Oscillator | 39.10 | 62.94 |
Price Performance
Historical ComparisonAbout HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.